Background-Noninvasive estimation of the degree of inflammation seen on kidney biopsy with lupus nephritis (LN) remains difficult. The objective of this study was to develop a Renal Activity Index for Lupus (RAIL) that, based solely on laboratory measures, accurately reflects
INTRODUCTION
Systemic Lupus Erythematosus (SLE) is a multi-system inflammatory autoimmune disease, and renal involvement is one of the main determinants of poor prognosis (1) . The pathogenesis of lupus nephritis (LN) involves kidney deposition of immune complexes in the setting of impaired apoptosis regulation (2) . There are three principal patterns of injury with LN. Firstly, a mesangial pattern which features mesangial hypercellularity and matrix deposits as a response to mesangial immune complex accumulation. Secondly, a proliferative pattern that occurs in response to subendothelial immune complex buildup and is characterized by obliteration of glomerular capillary lumens due to leukocyte accumulation, mesangial proliferation, often capillary wall destruction, and rupture of Bowman's capsule resulting in extra-capillary crescent formation. Lastly, in the membranous pattern there is increased immune complex deposition in the sub-epithelial space with leads to cytotoxic injury to the podocyte, and result in the thickening of the glomerular basement membrane. These three patterns are the basis for the categorization of LN in the International Society of Nephrology/Renal Pathology Society (ISN/PRS) Classification (3).
Recently, novel urine biomarkers (UBM) have been described that can assist with diagnosing active LN and anticipate LN flares (4 -8) . Among others, we have provided initial evidence that the urine concentrations of some of the UBMs are associated with distinct histological changes of LN (9) . Since our initial studies, additional UBMs have been proposed by other investigators. The 16 most promising of these UBMs were considered in this study: neutrophil gelatinase associated lipocalin (NGAL), monocyte chemotactic protein 1 (MCP-1), ceruloplasmin, adiponectin, hemopexin, kidney injury molecule 1 (KIM-1), alpha-1-acid glycoprotein (AAG), transforming growth factor beta (TGF-β), hepcidin, lipocalin-like prostaglandin synthase (L-PGDS), transferrin, vitamin D binding protein (VDBP), microalbumin, cystatin-C, endothelial protein C receptor (EPCR), and liver type fatty acid-binding protein 1 (L-FABP).
We hypothesized that a selection of these UBMs, alone or in combination with traditional measures of LN, can accurately quantify the degree of histological LN activity. Hence, the objective of this study was to develop in children and young adults a Renal Activity Index for Lupus (RAIL) to non-invasively measure LN activity.
MATERIALS & METHODS

Patients
Patients diagnosed with childhood-onset SLE (10) who required a kidney biopsy as part of standard of care participated in this cross-sectional study. At the time of kidney biopsy, a random urine sample was collected for UBM testing. Prospectively, relevant clinical information and traditional measures of LN were recorded, including the glomerular filtration rate (GFR) (11 , 12) and the protein to creatinine ratio (P/C ratio) in a random urine sample. All patients received therapy for childhood-onset SLE at the time of the urine collection and biopsy. There were five patients with repeat biopsies.
The renal domain score of the Systemic Lupus Disease Activity Index (SLEDAI-R; range 0 -16; 0 = inactive LN) (13) and that of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI-R; range 0-3; 0= no LN damage) (14) were also completed and served as measures of LN clinical activity and damage, respectively.
Kidney Histology
The histological characteristics of each kidney biopsy were interpreted in a blinded fashion by one expert nephropathologist (DW) as per the ISN/RPS Classification (3 , 15) . Most studies in LN employ a previously developed scoring system to quantify the amount of overall LN activity, using the National Institutes of Health Activity Index (NIH-AI; score range 0-24; 0= inactive) (16) . Because the NIH-AI is focused on acute glomerular injury with LN, we also measured the Tubulointerstitial Activity Index (TIAI; score range: 0-21; 0=no interstitial activity) (17) . The NIH Chronicity Index was scored (NIH-CI; score range 0 -12; 0 = no LN-chronicity) to quantify LN damage as seen on kidney biopsy (16) . The ISN/RPS Classification, the NIH-AI, TIAI and the NIH-CI have all been validated for use in children and adults (18 , 19) .
Urinary Biomarker Assays
The following 16 UBMs were measured: NGAL, MCP-1, ceruloplasmin, adiponectin, hemopexin, KIM-1, AAG, TGF-β, hepcidin, L-PGDS, transferrin, VDBP, microalbumin, EPRC, cystatin-C and L-FABP. Laboratory personnel assaying the UBMs were blinded to clinical and histological information. Spun urine samples were stored at 0°C within 1 hour of collection and frozen at −80°C prior within 24 hours prior to batch processing.
Unless stated otherwise, UBMs were quantified using commercial ELISA kits as per the manufacturers' instructions, and a four parameter logistic curve-fit was used to fit the standard curve. In the following, inter-assay and intra-assay variability of these assays is expressed in percent of the coefficient of variation [CV inter/intra]. (20) . Urine creatinine measurements were made using a modified Jaffe reaction, and microalbumin (MALB) was measured by immunoturbidimetry, both on a Dimension Xp and plus HM Clinical Analyzer (Siemens, Munich, Germany). Coefficients of variability for the creatinine measurements were 2.4% (intra) and 4.2% (total), and 2.9% (intra) and 5.9% (inter) for MALB.TGF-β [CV inter/intra: 2.6%/8.3%] was measured by ELISA (R&D Systems, Minneapolis, MN) after acid activation. Briefly, 20 μL of 1N HCl was added to 100 μL of urine sample, mixed by inversion and incubated at room temperature for 10 minutes. Next, the acidified sample was neutralized by adding 20 μL of 1.2 N NaOH/0. Concentrations of the UBMs (in ng/ml: for NGAL, CP, L-FABP, VDBP, adiponectin, EPCR, hemopexin, hepcidin; in pg/ml: for KIM-1 and TGF-β; in pg/ml: MCP-1: in mg/dl: for transferrin and L-PDGS; in mg/L for cystatin-C and microalbumin) were standardized for urine creatinine levels (in mg/mL).
Statistical analysis
The candidate predictors considered for inclusion in the RAIL were the 16 UBMs and the traditional measures of LN. LN-activity status served as the dependent variable in the statistical procedures to derive the RAIL and was defined as high versus (vs.) moderate/low based on the scores of the NIH-AI and TIAI, respectively. LN-Activity NIH-AI was classified as high when NIH-AI scores were >10, and moderate to low when NIH-AI scores were ≤10; LN-Activity TIAI was considered high for TIAI scores >5, and moderate to low for LNActivity TIAI scores ≤5. The pool of the candidate RAIL-predictors (standardized UBMs, traditional biomarkers) to be considered in the multivariate models was informed by univariate models under a threshold p-value of ≤0.2 for discrimination of high from moderate/low LN-activity (LN-activity NIH-AI ; LN-activity TIAI ). In primary analysis, stepwise selection was used in multiple logistical regression models to identify the components of the RAIL. In secondary analysis, we considered raw amounts of the UBMs rather than standardized UBMs. The appropriateness of the final RAIL predictors to reflect LN-activity status was confirmed by linear discriminant analysis (21) and principal component analysis, adjusted and unadjusted for LN chronicity (NIH-CI score).
The accuracies of RAIL algorithms was considered outstanding, excellent, good, and fair if the area under the receiver operating characteristic curve (AUC) was in the range of 0.9-1.0, 0.81-0.90, 0.71-0.80, and 0.61-0.70, respectively. We also determined sensitivity, specificity, the positive (LR+) and the negative likelihood ratios (LR−) for the statistical optimal receiver operating characteristic (ROC) curve cutoff. Here, LR+ values can be interpreted as: > 10: large, often conclusive increase in the likelihood of "ruling in" the presence of high LN-activity status; 5 -9.9: moderate increase; and 2 -4.9: small increase, respectively. In other words, a LR+ of 2 increases the probability for a high LN-activity status by 15%, a LR+ of 5 increases it 30%, and one of 10 increases it even by 45% (22) . LR − are interpreted accordingly for "ruling-out" active LN. Statistical analyses were done using SAS version 9.4 software (SAS, Cary, NC, USA). P-values < 0.05 were considered statistically significant. The study was approved by the Institutional Review Boards and Ethics Review Committees of the participating centers. Additional details on the statistical analyses are provided online.
RESULTS
Patient characteristics & features of kidney biopsy
A total of 47 patients with LN were included in this study (Table 1) . At the time of the study, on average, their [SD; standard deviation] age was 15.7 [3. 01] years, their extrarenal SLEDAI score was 9.7 [8.20] , and the time interval between kidney biopsy and urine collection was 0 [3] days. None of the patients had Class 1 or 6 LN. As expected, histological features of LN activity and chronicity were seen often concomitantly in the same biopsy. SDI-R scores were positive in 15 (32%) patients. Given the quality of the biopsy specimens, NIH-AI, TIAI and NIH-CI scores were not assigned to all biopsies, hence were only available for 41, 32 and 40 of the biopsies, respectively. The high and moderate/low NIH-AI consisted of 20 and 21 patients; there were 10 and 22 patients in the high and moderate/low TIAI as well as 21 patients with NIH-CI scores over 0.
Associations of noninvasive measures kidney histology indices
As is summarized in Table 2 , proteinuria did not significantly differentiate patients by LNactivity status (NIH-AI, TIAI) or LN-chronicity status (NIH-CI score > 0 vs. 0), irrespective of adjustment for angiotensinogen system blocking medications. The GFR was lower with high LN-activity status and with NIH-CI scores > 0. Seven UBMs significantly differed with LN-activity NIH-AI status and six UBMs with LN-activity TIAI status (Table 3) . Notably, MCP-1, adiponectin, and TGF-β significantly differed with both LN-activity NIH-AI and LNactivity TIAI status.
Associations of noninvasive measures kidney histology features
We then assessed the differential excretion of the UBMs with the presence vs. absence of individual histological findings reflective of active inflammation in LN (Figure 1) . NGAL, MCP-1, KIM-1 and L-PGDS were all markedly elevated in the urine of patients whose kidney biopsy showed endocapillary hypercellularity compared to those that did not. Likewise, NGAL, KIM-1 and MCP-1 were found in higher concentrations in patients whose kidney biopsy showed tubular cell flattening and necrosis. There were significantly higher urine levels of NGAL, but not MCP-1 or KIM-1, in patients with vs. without tubular cell pyknosis and epithelial cells in the tubular lumen. EPCR was not associated with any specific histological feature considered in the TIAI or NIH-AI; while TGF-β, AAG, cystatin-C and L-FABP were only differentially expressed with select histological features scored in the TIAI but with none of the features reflected by the NIH-AI.
Most of the UBMs were weakly (Pearson correlation coefficient r; |0.2| ≤ r < |0.4|) correlated with the P/C ratio but none was strongly correlated (r > |0.6|). The GFR was only moderately correlated with NGAL, weakly correlated only with MCP-1, VDBP, hemopexin and KIM-1, and unrelated to the levels of all other UBMs. Levels of complement C3 and C4 were no more than weakly correlated with any of the UBMs. As expected, the levels of UBMs were differentially associated with each other (see supplemental Figure 2 ).
UBMs and ISNPRS Class
The mean ( Table 3 compares means of LN measures between patients with and without LN activity, after correcting for concomitant LN damage ((NIH-CI score). In addition, each LN marker was used to predict LN activity using a ROC-analysis. The results revealed that KIM-1 was the single best UBM for capturing LN-activity NIH-AI status [AUC (95% CI): 0.86 (0.74, 0.98)] followed by MCP-1, NGAL and adiponectin which were at least good predictors [all AUCs (95% CI) ≥ 0.70 (0.54, 0.98)]. Irrespective of adjustment for concurrent kidney damage, MCP-1, VDBP, cystatin-C, TGF-β, L-PGDS and hemopexin were all at least good predictors of LN-activity TIAI status. Similarly, GFR was a good predictor of LN-activity status ( Table 2) .
Individual noninvasive LN measures and LN-activity status
Development of a combinatorial biomarker of LN-activity status
In stepwise multiple logistical modeling, we identified NGAL, ceruloplasmin, MCP-1, adiponectin, hemopexin and KIM-1 as the best predictors (RAIL-UBMs) of LN-activity TIAI status and LN-activity NIH-AI status (Figure 2 ; supplemental Tables 2). Traditional LN measures did not remain in the pool of covariates best suited to predict LN-activity status. The accuracy of the Rail-UBMs in reflecting the LN-activity status was well preserved in models correcting for concurrent LN damage (NIH-CI score) or even when considering simply the raw amounts of the RAIL-UBMs (Supplemental Figure 3) .
Besides multiple logistical regression models, other methods such as linear discriminant or principal component analyses have been shown to yield composite scores for measuring complex constructs. The suitability of the RAIL-UBMs for predicting histological correlates of active LN is supported by congruent results, using linear discriminate and principal component analyses (Table 4) .
Proposed RAIL algorithm
Given that the NIH-AI is more commonly used in clinical practice than the TIAI and because one must assume that information on LN chronicity will not readily be available in a clinical setting, we propose the following algorithm that considers log-transformed urine concentrations (creatinine standardized) of the six RAIL-UBMs: RAIL score = − 4.29 -0.34* NGAL −0.06*ceruloplasmin + 0.89* MCP-1+ 0.18* adiponectin − 0.65 * hemopexin + 0.62 * KIM-1. A RAIL-score of ≥ 0.39 will correctly identify 90% of all cases with high LN-activity status with a false positive rate being controlled at 14% (Figure 2, Panel A) .
DISCUSSION
At present, accurate of LN activity requires a kidney biopsy. Based on detailed assessment of the measurement properties of traditional and 16 novel urinary biomarkers of LN, we newly propose a Renal Activity Index for Lupus (RAIL) to noninvasively quantify LN activity. The accuracy of the RAIL is minimally influenced by concurrent LN chronicity and reflects both glomerular and tubulointerstitial inflammation with LN. Further, concurrent use of medications, including those targeting the renin-angiotensin-aldosterone system, do not seem to influence the accuracy of the RAIL to a large degree.
The UBMs included in the RAIL are all involved in putative mechanisms aimed at protecting kidneys from damage due to renal inflammation. Indeed, there is a strong biological rationale for each of the six RAIL UBMs. NGAL is rapidly induced by active inflammation with LN, and promptly declines with therapy (4). In the acute setting, NGAL appears to be a part of a protective anti-apoptotic mechanism that limits tubule cell damage and enhances proliferation (23) . MCP-1 is induced by type I interferons and is known to be a predictive biomarker of LN flares and LN severity (5 , 24) . There is high expression of MCP-1, especially in the tubular epithelial cells (25) with oxidative stress. The antioxidant ceruloplasmin is a copper-containing ferroxidase that can transform ferrous iron, which is highly damaging to kidney tubules, to its nontoxic ferric configuration. High ceruloplasmin levels are associated with renal tissue remodeling as can be observed with LN (4 , 26) .
The cytokine adiponectin is present on the endothelium of intrarenal vasculature and to a lesser extent in the proximal and distal tubular epithelial cells (27) , has anti-inflammatory properties, and urinary concentrations increase with kidney injury, including with LN. Among the UBMs considered, we found only adiponectin to be closely correlated with albuminuria. High levels of adiponectin levels were present in the setting of high glomerular and interstitial inflammation with LN.
Hemopexin, a protease that protects kidney tubules from toxicity of free heme radicals, is produced primarily in the renal cortex in the setting of nephrotoxic insults (28) . We found hemopexin levels closely related to glomerular leukocyte infiltrates, subendothelial deposits and interstitial inflammation with LN. The protective role of hemopexin in LN is supported by the observation that urine levels of hemopexin were highest with Class 2 LN (data not shown).
KIM-1 is responsible for the clearance of debris from damaged renal tubules and assists with the regeneration of the epithelium. Urine KIM-1 levels increase in the setting of proximal tubule injury and interstitial inflammation as can occur with LN (29).
One of our earlier studies suggested that the combination of MCP-1, ceruloplasmin, AAG and the P/C ratio has excellent accuracy in estimating histological LN activity (9) . While we confirm the usefulness of ceruloplasmin and MCP-1 in quantifying LN-activity, we believe that the current study has several new strengths. First, different from our earlier study, the majority of the urine samples were collected on the day of kidney biopsy and the interpretation of the kidney biopsies occurred by a single expert nephropathologist. Second, we increased the pool of candidate UBMs and assessed both tubulointerstitial and glomerular features of active inflammation with LN; and third, we considered concomitant LN damage. Nonetheless, previous results are in line with our current findings, given the association of the levels of the various UBMs with each other and also with distinct histological features of LN-activity (4 , 7 , 9) .
The UBMs considered in the RAIL were not well suited to discriminate between the different Classes of LN. Conversely, higher urine levels of two non-RAIL markers (L-FABP levels and cystatin-C) were associated with less severe LN (Class 2 as compared to Class 3, 4 or 5).
Our study must be seen in the light of certain limitations. Given the diverse medication regimens used, the multiplicity of distinct kidney biopsy features and their considerable overlap in a given patient, our study findings will need to be confirmed in a larger cohort. However, rigorous statistical methodology was employed and provided consistent results, irrespective of consideration of potential effect modifiers, supporting the robustness of our findings.
If confirmed in ongoing experiments, the RAIL will allow for more effective and personalized monitoring of LN and its therapy. The availability of standardized clinical platforms for the combined measurement of the urinary biomarkers will enable the testing of this hypothesis in the near future (30) . Future research will need to confirm the most appropriate cut-off scores for the RAIL and also investigate how the combinatorial RAILUBMs can be used to non-invasively predict response to therapy.
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LITERATURE SIGNIFICANCE & INNOVATIONS
•
We propose a renal activity index for lupus (RAIL) based on the urine concentrations of six protein biomarkers
The RAIL quantifies the amount of histological inflammation seen on kidney biopsy tissues as measured by the NIH Activity Index with over 92% accuracy
Once validated, it is anticipated that the RAIL is used to monitor the degree of inflammation with lupus nephritis non-invasively. Table 2 Levels of traditional laboratory measures and their relationship to LN histological indices. Accuracy of the combinatorial UBMs NGAL, ceruloplasmin, MCP-1, adiponectin, hemopexin and KIM-1 to reflect LN-activity study is preserved irrespective of the statistical approach used to derive the RAIL algorithm 
